GO:0140076 negative regulation of lipoprotein transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140076 (negative regulation of lipoprotein transport) describes any process that stops, prevents or reduces the frequency, rate or extent of lipoprotein transport, a critical determinant of systemic lipid distribution.
• Lipoprotein transport is a tightly regulated process; its negative regulation prevents excessive lipid delivery to peripheral tissues and helps maintain metabolic homeostasis.
• Key molecular players include apolipoproteins, lipoprotein receptors (e.g., LDLR, CD36), intracellular trafficking proteins (e.g., Rab1b, Spns1), and caveolar signaling components (e.g., eNOS).
• Dysregulation of negative regulation of lipoprotein transport contributes to familial chylomicronemia, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular disease.
• Experimental approaches to study this process include proteomics, transcriptomics, CRISPR knockout/knock-in models, and functional transport assays.
• EDITGENE provides CRISPR-based services (knockout, point mutation, knock-in, overexpression, library screening, bioinformatics) to dissect the genetic control of lipoprotein transport regulation.
Description
Lipoproteins are macromolecular assemblies that transport hydrophobic lipids, including cholesterol and triglycerides, through the aqueous bloodstream. The movement of these particles between tissues is essential for energy distribution and membrane synthesis, but excessive or misdirected lipoprotein transport can lead to lipid accumulation in arteries and peripheral organs. Consequently, cells and organisms have evolved mechanisms to negatively regulate lipoprotein transport, ensuring that lipid delivery is matched to metabolic demand. GO:0140076, negative regulation of lipoprotein transport, captures these inhibitory processes at the biological process level.
negative regulation of lipoprotein transport At A Glance
| GO ID | GO:0140076 |
|---|---|
| GO term | negative regulation of lipoprotein transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Inhibition of the frequency, rate or extent of lipoprotein transport |
| Related processes | Lipoprotein transport (GO:0042157), regulation of lipoprotein transport (GO:0140075) |
| Key regulators | Apolipoproteins, lipoprotein receptors, Rab GTPases, caveolar proteins |
| Disease relevance | Familial chylomicronemia, MASLD, cardiovascular disease |
| Research methods | CRISPR screens, proteomics, transcriptomics, transport assays |
What Is GO:0140076?
According to the Gene Ontology, GO:0140076 (negative regulation of lipoprotein transport) is defined as any process that stops, prevents or reduces the frequency, rate or extent of lipoprotein transport. This term encompasses molecular events that inhibit the movement of lipoprotein particles, including the regulation of apolipoprotein secretion, receptor-mediated uptake, intracellular trafficking, and signaling pathways that suppress lipoprotein transport activity.
Why Is negative regulation of lipoprotein transport Important in Cell Biology?
Negative regulation of lipoprotein transport is critical for preventing lipotoxicity and maintaining metabolic homeostasis. When this regulatory layer fails, excessive lipoprotein transport can drive pathologies such as hypertriglyceridemia, fatty liver disease, and atherosclerosis. Understanding the molecular mechanisms that inhibit lipoprotein transport provides insights into disease pathogenesis and identifies potential therapeutic targets for metabolic disorders.
• Prevents excessive lipid delivery to peripheral tissues, protecting against lipotoxicity.
• Maintains cholesterol homeostasis by balancing lipoprotein secretion and uptake.
• Dysregulation is linked to familial chylomicronemia and severe hypertriglyceridemia.
• Implicated in metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated oxidized LDL uptake.
• Modulates hepatitis C virus secretion, as Rab1b differentially regulates lipoprotein and HCV secretion.
• Involves iron transport via Spns1, linking metal homeostasis to megalin-dependent endocytosis.
• Caveolar eNOS signaling regulates lipoprotein transport in endothelial cells.
• Bacterial lipoprotein transport inhibition affects Pseudomonas aeruginosa transcriptional responses, highlighting conserved principles.
• Provides targets for CRISPR-based functional genomics in metabolic disease research.
• Offers opportunities for therapeutic intervention in cardiovascular and metabolic disorders.
What Happens During negative regulation of lipoprotein transport?
Inhibition of Lipoprotein Secretion
In simple terms: Cells can reduce the release of lipoproteins into the bloodstream.
Negative regulation of lipoprotein transport can occur at the level of secretion. For example, Rab1b differentially regulates lipoprotein and hepatitis C virus secretion, indicating that intracellular trafficking pathways can be modulated to reduce lipoprotein export. This step is critical for controlling postprandial lipid surges and preventing hypertriglyceridemia.
Suppression of Receptor-Mediated Uptake
In simple terms: Cells can decrease the uptake of lipoproteins from the blood.
Receptor-mediated endocytosis of lipoproteins, such as LDL uptake via LDLR or CD36, can be negatively regulated. CD36-mediated uptake of oxidized LDL induces ferroptosis in double-negative regulatory T cells, illustrating how uptake inhibition can impact immune cell survival in MASLD. Spns1, an iron transporter, is essential for megalin-dependent endocytosis, linking metal homeostasis to lipoprotein uptake regulation.
Intracellular Trafficking and Degradation
In simple terms: Cells can route lipoproteins for degradation instead of transport.
Intracellular trafficking proteins such as Rab GTPases and Spns1 influence whether lipoproteins are transported or targeted for degradation. Negative regulation may involve diverting lipoprotein particles to lysosomal degradation pathways, thereby reducing their availability for transport.
Signaling Pathways That Inhibit Transport
In simple terms: Signals from the environment can tell cells to stop transporting lipoproteins.
Caveolar signaling, including eNOS regulation, can modulate lipoprotein transport in endothelial cells. Additionally, small molecule inhibitors of lipoprotein transport in bacteria trigger transcriptional responses, suggesting conserved regulatory networks. In humans, hormonal and metabolic signals may suppress lipoprotein transport under conditions of energy surplus.
Transcriptional and Post-Transcriptional Control
In simple terms: Cells can turn down the production of proteins needed for lipoprotein transport.
Transcriptional responses to lipoprotein transport inhibition have been characterized in Pseudomonas aeruginosa, revealing gene expression changes that reduce transport capacity. In mammalian systems, proteomics and bioinformatics analyses of follicular fluid from PCOS patients identified differentially expressed proteins related to lipoprotein transport, suggesting transcriptional and post-transcriptional regulation.
Key Genes Involved in GO:0140076 negative regulation of lipoprotein transport
The following genes and proteins have been implicated in the negative regulation of lipoprotein transport based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOA1 | Structural component of HDL; modulates lipoprotein transport | Target for HDL-based therapies |
| APOB | Core component of LDL and chylomicrons; regulates secretion | Familial chylomicronemia and hypercholesterolemia |
| APOC3 | Inhibits lipoprotein lipase; delays clearance | Target for antisense inhibitors |
| LDLR | Mediates LDL uptake; negative regulation reduces uptake | Familial hypercholesterolemia |
| CD36 | Scavenger receptor for oxidized LDL; uptake regulation | MASLD and ferroptosis |
| RAB1B | Regulates secretion of lipoproteins and HCV | Viral and lipoprotein secretion |
| SPNS1 | Iron transporter; essential for megalin-dependent endocytosis | Lipoprotein uptake and metal homeostasis |
| NOS3 | Endothelial nitric oxide synthase; caveolar signaling | Vascular lipoprotein transport |
| MEGALIN | Endocytic receptor for lipoproteins | Renal and hepatic lipoprotein clearance |
| LPL | Hydrolyzes triglycerides in lipoproteins | Chylomicronemia and lipid metabolism |
| GPIHBP1 | Anchors LPL to endothelial cells | Chylomicronemia |
| APOC2 | Activates LPL | Familial chylomicronemia |
| LMF1 | Lipase maturation factor | Chylomicronemia |
| CREB3L3 | Transcription factor regulating lipid metabolism | Hypertriglyceridemia |
| ANGPTL3 | Inhibits LPL and endothelial lipase | Target for lipid-lowering therapies |
| ANGPTL4 | Inhibits LPL | Regulation of triglyceride uptake |
| PCSK9 | Promotes LDLR degradation | Hypercholesterolemia therapy target |
How Is negative regulation of lipoprotein transport Regulated?
Negative regulation of lipoprotein transport is controlled at multiple levels. Transcriptional regulation involves nuclear receptors and transcription factors that respond to lipid status. Post-transcriptional mechanisms include microRNAs and RNA-binding proteins that affect mRNA stability of transport-related genes. Signaling pathways such as caveolar eNOS signaling modulate transport activity acutely. Additionally, small molecule inhibitors can trigger global transcriptional responses that suppress lipoprotein transport, as shown in Pseudomonas aeruginosa. In mammals, hormonal signals (insulin, glucagon) and nutrient sensors (AMPK, mTOR) likely integrate to fine-tune lipoprotein transport, though specific mechanisms require further study.
negative regulation of lipoprotein transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPL | Familial chylomicronemia | Lpl knockout mouse; CRISPR knock-in of patient mutations |
| CD36 | MASLD, ferroptosis | Cd36 knockout hepatocytes; overexpression in T cells |
| RAB1B | HCV secretion, lipoprotein transport | RAB1B knockout Huh7 cells; tagged knock-in |
| SPNS1 | Lipoprotein endocytosis, iron transport | Spns1 knockout renal cells; rescue with wild-type |
| NOS3 | Cardiovascular disease, caveolar signaling | Nos3 knockout endothelial cells; overexpression |
Familial Chylomicronemia
Familial chylomicronemia is a rare genetic disorder characterized by severe hypertriglyceridemia due to defective clearance of chylomicrons. Mutations in LPL, APOC2, GPIHBP1, and LMF1 impair lipoprotein transport regulation, leading to chylomicron accumulation. Negative regulation of lipoprotein transport is therefore critical for preventing this condition.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
In MASLD, CD36-mediated uptake of oxidized LDL induces ferroptosis in double-negative regulatory T cells, exacerbating liver inflammation and injury. Negative regulation of lipoprotein transport may protect against lipid overload and immune cell death in the liver.
Cardiovascular Disease
Dysregulated lipoprotein transport contributes to atherosclerosis. Negative regulation of transport, such as reducing LDL uptake or enhancing reverse cholesterol transport, is a therapeutic goal. Caveolar eNOS signaling influences endothelial lipoprotein handling and vascular health.
Infectious Disease
Hepatitis C virus exploits lipoprotein secretion pathways; Rab1b differentially regulates lipoprotein and HCV secretion, suggesting that negative regulation of lipoprotein transport may also impact viral propagation.
From negative regulation of lipoprotein transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate lipoprotein secretion? | CRISPR knockout in hepatocytes followed by lipoprotein secretion assay |
| Does point mutation Y affect transport inhibition? | CRISPR point mutation knock-in in cell lines; transport assays |
| Does overexpression of gene Z reduce lipoprotein uptake? | CRISPR overexpression (CRISPRa) or lentiviral overexpression |
| Which genes are essential for negative regulation? | Genome-wide CRISPR knockout library screening |
| How does tagging affect protein localization? | Tagged knock-in (e.g., GFP) followed by imaging |
| What are the transcriptomic changes upon transport inhibition? | RNA-seq after CRISPR knockout of key regulators |
How to Study the negative regulation of lipoprotein transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Proteomics | Protein abundance and modifications | Identify regulators in patient samples |
| RNA-seq | Transcriptional changes | Global responses to transport inhibition |
| CRISPR knockout screen | Gene essentiality for transport regulation | Discover negative regulators |
| CRISPR activation screen | Gene overexpression effects | Identify suppressors of transport |
| Fluorescent lipoprotein uptake | Rate of lipoprotein internalization | Quantify negative regulation |
| Secretion assay | Lipoprotein release into medium | Assess secretion inhibition |
| Imaging (confocal) | Subcellular localization of transport proteins | Track trafficking |
Proteomics and Bioinformatics
Proteomics and bioinformatics analyses can identify differentially expressed proteins related to lipoprotein transport. For example, follicular fluid from PCOS patients revealed alterations in proteins involved in lipid transport. Such approaches can uncover novel regulators of negative regulation of lipoprotein transport.
Transcriptomics
RNA-seq and microarray analyses can reveal transcriptional responses to inhibition of lipoprotein transport. In Pseudomonas aeruginosa, small molecule inhibitors induced specific transcriptional changes. Similar approaches in mammalian cells can identify genes that mediate negative regulation.
Functional Transport Assays
Lipoprotein transport can be measured using fluorescently labeled lipoproteins, radioactive tracers, or biochemical assays. These methods allow direct assessment of whether a gene or treatment negatively regulates transport.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can systematically identify genes that negatively regulate lipoprotein transport. Such screens have been used to dissect complex metabolic pathways and can be adapted to lipoprotein transport.
How CRISPR Can Be Used to Study GO:0140076 negative regulation of lipoprotein transport
Knockout
CRISPR knockout of candidate genes (e.g., RAB1B, CD36, SPNS1) can determine whether they are required for negative regulation of lipoprotein transport. For example, RAB1B knockout alters lipoprotein secretion, and CD36 knockout affects oxidized LDL uptake.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants in genes like LPL or APOC2 to assess their impact on lipoprotein transport regulation. This approach provides precise genotype-phenotype correlations.
Knock-in
Tagged knock-in (e.g., GFP, HA) allows visualization and immunoprecipitation of transport-related proteins to study their localization and interactions. Knock-in of reporter genes can also monitor transport activity in real time.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increasing gene dosage enhances negative regulation of lipoprotein transport. Overexpression of ANGPTL3 or ANGPTL4, for instance, inhibits lipoprotein lipase and reduces transport.
How EDITGENE Supports negative regulation of lipoprotein transport Research
Researchers studying negative regulation of lipoprotein transport-related genes often need to determine whether a candidate gene is causally involved in inhibiting lipoprotein transport, and to dissect the underlying molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipoprotein transport research.
Frequently Asked Questions About negative regulation of lipoprotein transport
What is GO:0140076?
GO:0140076 is the Gene Ontology term for negative regulation of lipoprotein transport, defined as any process that stops, prevents or reduces the frequency, rate or extent of lipoprotein transport.
What genes are involved in negative regulation of lipoprotein transport?
Key genes include APOA1, APOB, APOC3, LDLR, CD36, RAB1B, SPNS1, NOS3, LPL, GPIHBP1, APOC2, LMF1, ANGPTL3, ANGPTL4, and PCSK9.
How is lipoprotein transport negatively regulated?
It is regulated at multiple levels, including inhibition of secretion, suppression of receptor-mediated uptake, intracellular trafficking, and signaling pathways such as caveolar eNOS signaling.
What diseases are associated with defective negative regulation of lipoprotein transport?
Familial chylomicronemia, MASLD, cardiovascular disease, and hepatitis C virus infection have been linked to dysregulated lipoprotein transport.
What experimental models are used to study negative regulation of lipoprotein transport?
CRISPR knockout/knock-in cell lines, overexpression models, and animal models such as Lpl knockout mice are commonly used.
How can CRISPR screening help identify negative regulators of lipoprotein transport?
Genome-wide CRISPR knockout or activation screens can systematically identify genes whose loss or gain affects lipoprotein transport, revealing novel regulatory pathways.
What is the role of CD36 in lipoprotein transport regulation?
CD36 mediates uptake of oxidized LDL; its regulation can induce ferroptosis in T cells and is implicated in MASLD.
How does Rab1b regulate lipoprotein transport?
Rab1b differentially regulates lipoprotein and hepatitis C virus secretion, affecting intracellular trafficking.
What is the connection between Spns1 and lipoprotein transport?
Spns1 is an iron transporter essential for megalin-dependent endocytosis, linking metal homeostasis to lipoprotein uptake.
Why is negative regulation of lipoprotein transport important for health?
It prevents excessive lipid delivery, maintains cholesterol homeostasis, and protects against hypertriglyceridemia, fatty liver disease, and atherosclerosis.
Conclusion
Negative regulation of lipoprotein transport (GO:0140076) is a vital biological process that controls lipid distribution and protects against metabolic disease. Key genes such as CD36, RAB1B, SPNS1, and NOS3 have been implicated in this regulation, and dysregulation contributes to familial chylomicronemia, MASLD, and cardiovascular disease. Continued research using CRISPR-based models and multi-omics approaches will further elucidate these mechanisms and identify therapeutic targets.
References
- 1. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 2. Wang W et al.. 2022. Proteomics and bioinformatics analysis of follicular fluid from patients with polycystic ovary syndrome.. Front Mol Biosci 9:956406 PMID: 36072434
- 3. Wei Y et al.. 2025. CD36-mediated uptake of oxidized LDL induces double-negative regulatory T cell ferroptosis in metabolic dysfunction-associated steatotic liver disease.. Metabolism 164:156127 PMID: 39743040
- 4. Takacs CN et al.. 2017. Differential Regulation of Lipoprotein and Hepatitis C Virus Secretion by Rab1b.. Cell Rep 21(2):431-441 PMID: 29020629
- 5. Beenken A et al.. 2024. Spns1 is an iron transporter essential for megalin-dependent endocytosis.. Am J Physiol Renal Physiol 327(5):F775-F787 PMID: 39265081
- 6. Quiroga-Padilla PJ et al.. 2020. [Familial chylomicronemia].. Medicina (B Aires) 80(4):348-358 PMID: 32841138
- 7. Lorenz C et al.. 2020. Transcriptional Responses of Pseudomonas aeruginosa to Inhibition of Lipoprotein Transport by a Small Molecule Inhibitor.. J Bacteriol 202(24) PMID: 32989085
- 8. Mineo C et al.. 2012. Regulation of eNOS in caveolae.. Adv Exp Med Biol 729:51-62 PMID: 22411313
